Champions Oncology, Inc.: Form 10-Q for the period ended Jan 31, 2018
Filed with the SEC on Mar 19, 2018 and accepted by EDGAR at Mar 19, 2018, 16:30 ET.
Management's discussion and analysis
As filed, 15,185 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion of our historical results of operations and our liquidity and capital resources should be read in conjunction with the condensed consolidated financial statements and related notes that appear elsewhere in this report and our most recent annual report for the year ended April 30, 2017, as filed on Form 10-K.
Forward-Looking Statements
This Quarterly Report on Form 10-Q contains certain “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources. These forward-looking statements include, without limitation, statements regarding: proposed new programs; expectations that regulatory developments or other matters will not have a material adverse effect on our financial position, results of operations, or liquidity; statements concerning projections, predictions, expectations, estimates, or forecasts as to our business, financial and operational results, and future economic performance; and statements of management’s goals and objectives and other similar expressions concerning matters that are not historical facts. Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar expressions, as well as statements in future tense, identify forward-looking statements.
Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.
Forward-looking statements speak only as of the date the statements are made. Factors that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited to, those described in “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended April 30, 2017, as updated in our subsequent reports filed with the SEC, including any updates found in Part II, Item 1A of this or other reports on Form 10-Q. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions, or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Overview and Recent Developments
We are engaged in the development and sale of advanced technology solutions and products utilized in the development and use of oncology drugs. Utilizing our TumorGraft Technology Platform, we provide select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. By performing studies to predict the efficacy of oncology drugs, our Platform facilitates drug discovery with lower costs and increased speed of drug development as well as increased adoption of existing drugs.
Our platform provides a novel approach to simulating the results of human clinical trials used in developing oncology drugs. According to a 2013 study conducted by Cutting Edge Information, it can cost up to $100,000 per patient in oncology clinical trials and the typical cost for each phase of development per year increases from approximately $3 million in the pre-clinical setting to approximately $150 million in phase III. Simulating trials before executing them provides benefits to both pharmaceutical companies and patients. Pharmaceutical companies can lower the risk of spending resources on drugs that do not show significant anti-cancer activities and increase the chance that the clinical development path they pursue will be focused on an appropriate patient population and a successful combination with other drugs.
We plan to continue our efforts to expand our TumorGraft Technology Platform in order to expand our TOS program. Our POS program will not be the focus of our growth moving forward.
Liquidity and Capital Resources
Our liquidity needs have typically arisen from the funding of our research and development programs and the launch of new products, working capital requirements, and strategic initiatives. In the past, we have met these cash requirements through our sales of products and services, working capital management, and proceeds from certain private and public offerings of our securities. For the nine months ended January 31, 2018, we had a net loss of $844,000 and net operating cash outflows of $1.2 million. In addition, as of January 31, 2018, we had negative working capital of $2.0 million and cash and cash equivalents on hand of $1.1 million. The reduction of cash from year-end was mainly due to the $910,000 investment in equipment for our new lab facility along with the realization of deferred revenue, timing of accounts receivable collections and expense payments in the normal course of business. Additionally, we incurred approximately $100,000 of non-capitalized, non-recurring costs related to the new lab set-up. Finally, we closed on a line of credit ("LOC") agreement which provides that the Company may borrow up to $1.5 million. The Company does not plan to utilize the LOC as we believe that our cash and cash equivalents on hand at January 31, 2018 and future revenue are adequate to fund our operations through at least December 2018.
However, in order for us to continue our operations beyond March 2019, we need to continue to increase revenues while managing increases in expense levels. If we are unable to maintain our operating levels, we may need to obtain capital from external sources. If we could not obtain additional financing, we may be required to reduce the scope of, or delay or eliminate, some of our research and development and other activities, which could harm our financial condition and operating results. Financing may not be available on acceptable terms or at all, and our failure to raise capital when needed could negatively impact our growth plans and our financial condition and results of operations. Additional equity financing may be dilutive to the holders of our common stock and debt financing, if available, may involve significant cash payment obligations and covenants and/or financial ratios that could restrict our ability to operate our business.
Operating Results
The following table summarizes our operating results for the periods presented below (dollars in thousands):
| Operating revenue: | For the Three Months Ended January 31, 2018 | % of Revenue | 2017 | % of Revenue | % Change |
|---|---|---|---|---|---|
| Personalized oncology solutions | $259 | 5.1% | $347 | 9.7% | (25.4)% |
| Translational oncology solutions | 4,823 | 94.9 | 3,218 | 90.3 | 49.9% |
| Total operating revenue | 5,082 | 100.0 | 3,565 | 100.0 | 42.6 |
| Costs and operating expenses: | |||||
| Cost of personalized oncology solutions | 220 | 4.3 | 320 | 9.0 | (31.3) |
| Cost of translational oncology solutions | 2,253 | 44.3 | 2,086 | 58.5 | 8.0 |
| Research and development | 1,045 | 20.6 | 998 | 28.0 | 4.7 |
| Sales and marketing | 627 | 12.3 | 726 | 20.4 | (13.6) |
| General and administrative | 1,004 | 19.8 | 836 | 23.5 | 20.1 |
| Total costs and operating expenses | 5,149 | 101.3 | 4,966 | 139.4 | 3.7 |
| Loss from operations | $(67) | (1.3)% | $(1,401) | (39.4)% | (95.2)% |
| Operating revenue: | For the Nine Months Ended January 31, 2018 | % of Revenue | 2017 | % of Revenue | % Change |
|---|---|---|---|---|---|
| Personalized oncology solutions | $1,077 | 7.0% | $1,354 | 11.6% | (20.5)% |
| Translational oncology solutions | 14,242 | 93.0 | 10,337 | 88.4 | 37.8 |
| Total operating revenue | 15,319 | 100.0 | 11,691 | 100.0 | 31.0 |
| Costs and operating expenses: | |||||
| Cost of personalized oncology solutions | 871 | 5.7 | 1,167 | 10.0 | (25.4) |
| Cost of translational oncology solutions | 6,866 | 44.8 | 5,965 | 51.0 | 15.1 |
| Research and development | 3,308 | 21.6 | 3,217 | 27.5 | 2.8 |
| Sales and marketing | 1,862 | 12.2 | 2,369 | 20.3 | (21.4) |
| General and administrative | 3,167 | 20.7 | 3,393 | 29.0 | (6.7) |
| Total costs and operating expenses | 16,074 | 104.9 | 16,111 | 137.8 | (0.2) |
| Loss from operations | $(755) | (4.9)% | $(4,420) | (37.8)% | (82.9)% |
17
Operating Revenues
Operating revenues were $5.1 million and $3.6 million for the three months ended January 31, 2018 and 2017, respectively, an increase of $1.5 million or 42.6%. Operating revenues were $15.3 million and $11.7 million for the nine months ended January 31, 2018 and 2017, respectively, an increase of $3.6 million or 31%.
POS revenues were $259,000 and $347,000 for the three months ended January 31, 2018 and 2017, respectively, a decrease of $88,000, or (25.4%). The decrease is due mainly to a decrease in implant and drug study revenue. POS revenues were $1 million and $1.4 million for the nine months ended January 31, 2018 and 2017, respectively, a decrease of $400,000 or (20.5%).
TOS revenues were $4.8 million and $3.2 million for the three months ended January 31, 2018 and 2017, respectively, an increase of $1.6 million, or 49.9%. TOS revenues were $14.2 million and $10.3 million for the nine months ended January 31, 2018 and 2017, respectively, an increase of $3.9 million, or 37.8%.
Cost of Personalized Oncology Solutions
Cost of POS for the three months ended January 31, 2018 and 2017 were $220,000 and $320,000, respectively, a decrease of $100,000, or (31.3%). Cost of POS for the nine months ended January 31, 2018 and 2017 were $900,000 and $1.2 million, respectively, a decrease of $300,000 or (25.4%). For the three months ended January 31, 2018 and 2017, gross margins for POS were 15.1% and 7.8%, respectively. The improvement is attributed to the increase in higher margin sequencing revenue. For the nine months ended January 31, 2018 and 2017, gross margins for POS were 19.1% and 13.8%, respectively.
Cost of Translational Oncology Solutions
Cost of TOS for the three months ended January 31, 2018 and 2017 were $2.3 million and $2.1 million, respectively, an increase of $200,000, or 8%. Cost of TOS for the nine months ended January 31, 2018 and 2017 was $6.9 million and $6 million, respectively, an increase of $900,000, or 15.1%. For the three months ended January 31, 2018 and 2017, gross margins for TOS were 53.3% and 35.2%, respectively. The increase in TOS cost of sales was due to an increase in the number and size of TOS studies. The gross margin often fluctuates quarter to quarter, resulting from timing differences between revenue and expense recognition. For the nine months ended January 31, 2018 and 2017, gross margins for TOS were 51.8% and 42.3%, respectively.
Research and Development
Research and development expenses for the three months ended January 31, 2018 and 2017 were $1.0 million. Research and development expenses for the nine months ended January 31, 2018 and 2017 were $3.3 million and $3.2 million, respectively, an increase of $100,000, or 2.8%.
Sales and Marketing
Sales and marketing expenses for the three months ended January 31, 2018 and 2017 were $627,000 and $726,000, respectively, a decrease of $99,000, or (13.6%). The decrease is mainly due to a reduction of marketing resources for the POS division. Sales and marketing expenses for the nine months ended January 31, 2018 and 2017 was $1.9 million and $2.4 million, respectively, a decrease of $500,000 or (21.4%).
General and Administrative
General and administrative expenses for the three months ended January 31, 2018 and 2017 were $1 million and $836,000, respectively, an increase of $164,000, or 20.1%. General and administrative expenses for the nine months ended January 31, 2018 and 2017 were $3.2 million and $3.4 million, respectively, a decrease of $200,000 or (6.7%).
Inflation
Inflation does not have a meaningful impact on the results of our operations.
Cash Flows
The following discussion relates to the major components of our cash flows:
Cash Flows from Operating Activities
Net cash used in operating activities was $1.2 million for the nine months ended January 31, 2018 compared to $3.2 million for the nine months ended January 31, 2017, respectively.
Cash Flows from Investing Activities
Net cash used in investing activities was $1 million and $181,000 for the nine months ended January 31, 2018 and 2017, respectively. These current cash outflows were primarily due to the purchase of property and equipment relating to the Company's new lab facility in Rockville, Maryland.
Cash Flows from Financing Activities
Net cash provided by financing activities was $19,000 and $4.3 million for the nine months ended January 31, 2018 and 2017, respectively. The net cash used in financing activities relates to our capital lease and the exercise of stock options.
Critical Accounting Estimates and Policies
The preparation of these condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to apply methodologies and make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates of the Company include, among other things, accounts receivable realization, revenue recognition (replacement of licensed tumors), valuation allowance for deferred tax assets, valuation of goodwill, and stock compensation and warrant assumptions. Actual results could differ from those estimates. The Company’s critical accounting policies are summarized in the Company’s Annual Report on Form 10-K, filed with the SEC on July 28, 2017.
Recent Accounting Pronouncements
For detailed information regarding recently issued accounting pronouncements and the expected impact on our condensed consolidated financial statements, see Note 8, "Recent Accounting Pronouncements" in the accompanying Notes to Condensed Consolidated Financial Statements included in Item 1 of this Report on Form 10-Q.
Off-Balance Sheet Financing
We have no off-balance sheet debt or similar obligations. We have no transactions or obligations with related parties that are not disclosed, consolidated into or reflected in our reported results of operations or financial position. We do not guarantee any third-party debt.
Controls and procedures
As filed, 1,601 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
It is management’s responsibility to establish and maintain “disclosure controls and procedures” as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934. Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer have reviewed and evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this quarterly report. Based on that evaluation, our management, including our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of January 31, 2018 at the reasonable assurance level in ensuring that information required to be disclosed in the reports that we file or submit under the Securities Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and our Chief Financial Officer as appropriate, to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting in connection with the evaluation required by Rule 13a-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 2,564 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We may not be able to meet our cash requirements beyond March 2019 without reducing the scope of our activities or obtaining additional capital from external sources, and if we are unable to do so, we may not be able to continue as a going concern.
Our liquidity needs have typically arisen from the funding of our research and development programs and the launch of new products, working capital requirements, and strategic initiatives. In the past, we have met these cash requirements through our sales of products and services, working capital management, and proceeds from certain private and public offerings of our securities. For the nine months ended January 31, 2018, we had a net loss of $844,000 and net operating cash outflows of $1.2 million. In addition, as of January 31, 2018, we had negative working capital of $2.0 million and cash and cash equivalents on hand of $1.1million. The reduction of cash from year-end was mainly due to the $910,000 investment in equipment for our new lab facility along with the realization of deferred revenue, timing of accounts receivable collections and expense payments in the normal course of business. Additionally, we incurred approximately $100,000 of non-capitalized, non-recurring costs related to the new lab set-up. Finally, we closed on a line of credit ("LOC") agreement which provides that the Company may borrow up to $1.5 million. The Company does not plan to utilize the LOC as we believe that our cash and cash equivalents on hand at January 31, 2018 and future revenue are adequate to fund our operations through at least December 2018.
However, in order for us to continue our operations beyond March 2019, we need to continue to increase revenues while managing increases in expense levels. If we are unable to maintain our operating levels, we may need to obtain capital from external sources. If we could not obtain additional financing, we may be required to reduce the scope of, or delay or eliminate, some of our research and development and other activities, which could harm our financial condition and operating results. Financing may not be available on acceptable terms or at all, and our failure to raise capital when needed could negatively impact our growth plans and our financial condition and results of operations. Additional equity financing may be dilutive to the holders of our common stock and debt financing, if available, may involve significant cash payment obligations and covenants and/or financial ratios that could restrict our ability to operate our business.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-01-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2017-11-01 to 2018-01-31 | $1.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2017-05-01 to 2018-01-31 | $3.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2017-11-01 to 2018-01-31 | −$67.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2017-05-01 to 2018-01-31 | −$755.0k | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2017-11-01 to 2018-01-31 | $2.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2017-05-01 to 2018-01-31 | $18.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-11-01 to 2018-01-31 | −$76.0k | us-gaap:NetIncomeLoss |
| Net income | 9 months2017-05-01 to 2018-01-31 | −$844.0k | us-gaap:NetIncomeLoss |
| Operating cash flow | 9 months2017-05-01 to 2018-01-31 | −$1.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2017-05-01 to 2018-01-31 | $1.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2018-01-31 | $1.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-01-31 | $4.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-01-31 | $7.1m | us-gaap:Assets |
| Current liabilities | At period end2018-01-31 | $6.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-01-31 | $6.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2018-01-31 | $472.0k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-18-003346. Last ingested by Listed: Nov 10, 2026, 03:33 ET. Listed shows no prices and gives no investment advice.